EAU Edu Platform UROONCO
LightNews LightNews
eau-uroonco.bsky.social
EAU Edu Platform UROONCO
@eau-uroonco.bsky.social
20 followers 13 following 1 posts
The EAU Edu Platform for all healthcare professionals in uro-oncology. UROONCO is an initiative of the EAU in close collaboration with ESU and European Urology.
Posts Replies Media Videos
eau-uroonco.bsky.social
📰 The RCC Article of the Month features the results of the first ever #kidneycancer screening trial, with the use of abdominal noncontrast computed tomography scanning. Read the full article with expert commentary from Dr. Teele Kuusk. 👇

kidney.uroonco.uroweb.org/publication/...
Abdominal noncontrast computed tomography scanning to screen for kidney cancer and other abdominal pathology within community-based computed tomography screening for lung cancer: Results of the Yorksh...
The Yorkshire Kidney Screening Trial assessed the feasibility of adding abdominal noncontrast CT to lung cancer screening to screen for RCC and other abdominal pathology.
kidney.uroonco.uroweb.org
January 29, 2025 at 3:17 PM
Reposted by EAU Edu Platform UROONCO
uroweb.org
AI technology has matured enough to make this a possibility and should help delegates who might not be fluent in English.

uroweb.org/news/ai-powe...
AI-powered live translation to be offered at EAU25 - Uroweb
The EAU is proud to offer live translation for most sessions at the Annual Congress! Access translations in 60 languages via your phone as captions or audio, making sessions more accessible than ever.
uroweb.org
December 10, 2024 at 8:47 AM
Reposted by EAU Edu Platform UROONCO
uroweb.org
New Cheat Sheet: This document covers adjuvant chemotherapy and immunotherapy roles, recent advancements in metastatic UC treatment, and combination therapy standards like EV + Pembrolizumab.

#MIBC #BladderCancer #EAUguidelines

Download the Cheat Sheet here:
uroweb.org/guidelines/m...
New Cheat Sheet on Muscle-invasive and Metastatic Bladder Cancer: This document covers adjuvant chemotherapy and immunotherapy roles, recent advancements in metastatic UC treatment, and combination therapy standards like EV + Pembrolizumab. Key points include eligibility criteria, survival outcomes, and managing immune-related adverse effects.
January 9, 2025 at 2:16 PM